Northwire Canada EditionSunday, October 18, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Earnings

Perimeter Medical Imaging AI Announces Strong Third Quarter 2025 Financial Results

By The Northwire Desk — AI Analysis Nov 12, 2025 · 16:59 PINK · 0.24 Perimeter Medical Imaging AI, Inc.
PINK · Price

Executive Summary

  • Q3‑2025 revenue jumped 157% YoY to $536,000, delivering a record nine‑month total of $1.6 M (up 88% vs. 2024).
  • Operating expenses fell 34% YoY and 30% QoQ to ~$3.0 M, narrowing the net loss to $2.7 M ($0.03 per share) – a 42% improvement over Q3‑2024.
  • The company continues to advance its FDA‑cleared S‑Series OCT system while progressing the investigational B‑Series AI‑enabled device toward commercialization, with a pivotal trial underway and a new OCT‑Tissue Surveillance Registry launched.

Key Details

  • Revenue: $536,000 in Q3‑2025 (↑157% YoY, ↑6% QoQ).
  • Nine‑month revenue: $1.6 M (↑88% vs. full‑year 2024).
  • Operating expenses: ~$3.0 M (↓34% YoY, ↓30% QoQ) – driven by lower clinical trial costs and company‑wide cost cuts implemented June 2025.
  • Net loss: $2.7 M, or $0.03 per common share (↑42% improvement vs. Q3‑2024).
  • Cash balance: Approximately $1.7 M as of September 30, 2025.
  • Commercial traction – S‑Series: Over 3,500 patients imaged to date (↑17% since August); new installation at Medical City Dallas Hospital.
  • Regulatory update: FDA continues substantive review of the PMA for the B‑Series; decision anticipated H1‑2026.
  • Clinical activity: Launch of OCT‑Tissue Surveillance Registry to collect thousands of surgical images for AI model training.
  • Leadership addition: Dr. Ted James appointed Chief Medical Officer (CMO) in August 2025.
  • Financing recap: July 2025 closing of a prospectus offering raised ~US$1.6 M gross proceeds from 7,416,667 units at the offering price; additional units and warrants issued to insiders and agents.
  • Conference call: Live webcast scheduled for today (Nov 12) at 5:00 pm ET; dial‑in numbers provided.

Notable Quotes

“The strong business momentum from the second quarter carried through the third quarter, reinforcing the traction we are building across our commercial and development initiatives,” – Adrian Mendes, CEO.

All amounts are in U.S. dollars unless otherwise noted.

Read the original news release →

More from Perimeter Medical Imaging AI, Inc.

Jun 09, 2026 · 09:05

FDA-approved AI surgical imaging pioneer secures minor R&D grant as commercial ramp remains early-stage and cash-burn persists

Other May 28, 2026 · 16:40

Perimeter Medical Imaging AI

Earnings Apr 29, 2026 · 08:00

Perimeter Showcases FDA-Approved Claire System at ASBrS 2026

Other Apr 28, 2026 · 08:15

CEO Insider Commitment Validates FDA Milestone But Dilution Concerns Persist Amidst Consolidation

Financings Apr 21, 2026 · 07:15

Perimeter Medical Imaging AI Secures Lifeline Financing at Discount to Market Price Amidst Cash Burn Concerns

Financings Mar 31, 2026 · 16:15

Perimeter Clears FDA Hurdle and Posts Record Sales, But Cash Runway and Dilution Threaten Near-Term Upside

Earnings